Rempex awarded BARDA contract worth up to $90 million
Carbavance is created with a combination of carbapenem antibiotics and a beta-lactamase inhibitor. In a preclinical study, Carbavance showed effectiveness against a number of critical gram-negative pathogens, including Acinetobacter sp., Klebsiella sp., Pseudomonas aeruginosa and E. coli.
The BARDA contract is a cost-sharing agreement for the nonclinical development, clinical studies, manufacturing and all activities related to gaining approval U.S. approval of Carbavance as a treatment agaisnt severe gram-negative infections. The agreement also includes plans to research the potential use of Carbavance against gram-negative bioterrorism agents.
The initial agreement includes a commitment of $19.8 million for treatment development, with options for longer than five years that would increase the value of the contract to approximately $90 million.
Rempex is a wholly-owned subsidiary of the Medicines Company, which acquired the pharmaceutical company at the end of last year. Carbavance is expected to enter registration studies this year and has already successfully completed Phase 1 dose-escalation studies.
Carbavance is only one of Rempex's drug candidates, which interested the Medicines Company in its acquisiton of the pharmaceutical company.